menu search

Clinical ink Selected for Global Late Phase Parkinson’s Disease Programs

Clinical ink Selected for Global  Late Phase Parkinson’s Disease Programs
Combining eCOA and Ground-Breaking Movement Disorders Digital Biomarker Platform to Evaluate and Predict PD Severity. Horsham, PA, Dec. 14, 2022 (GLOBE NEWSWIRE) — Horsham, Pa.; December 14, 2022 — Clinical ink, a global life science technology company, has partnered with a leading biopharmaceutical organization focused on Parkinson’s Disease research to deploy remote technology that captures study participants’ […] The post Clinical ink Selected for Global Late Phase Parkinson’s Disease Progra... Read More
Posted: Dec 14 2022, 15:47
Author Name: forextv
Views: 111817

Search within

Pages Search Results: